Close
GS1 Global Healthcare Conference 2026
Medica Compamed 2026

Cook Medical Showcases Latest Advancements for Treating Vascular Disease at ISET 2010

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Revvity Launches GSP T1D 3plex Kit...

Revvity has launched the GSP T1D 3plex kit, a...

The Cigna Group Partners with OpenAI...

The Cigna Group has entered into a strategic partnership...

WHO Expands Prequalification Programme for Medical...

The World Health Organization (WHO) has announced a major...

Cook Medical is presenting its latest advancements at the ISET 2010 International Symposium on Endovascular Therapy. In addition to live and simulated device demonstrations in booth #208, Cook's activities at the meeting include data presentations from two ongoing clinical trials and breakout sessions on common and debilitating conditions such as varicocele.

Rob Lyles, vice president and global leader of Cook's peripheral intervention business unit said, The number of people affected by some form of peripheral vascular disease is increasing at alarming rates worldwide,” said Rob Lyles, vice president and global leader of Cook's peripheral intervention business unit. Awareness is a fundamental line of attack for us against these spiking numbers. It is our mission to inform patients and physicians alike about the intricacies surrounding treatments that span the entire vascular disease spectrum and arm them with the technologies needed to improve outcomes.

Findings from the REFORM clinical trial evaluating the Formula™ Balloon Expandable Stent for the long-term treatment of renal artery stenosis following suboptimal angioplasty are being presented by Dr. Robert Bersin, medical director of endovascular services at Seattle Cardiology and Swedish Medical Center. Early data from the single-arm, 100-patient study suggest high technical and procedural success rates, clinically significant reductions in systolic blood pressure at one month, stable renal function, and no evidence of safety concern. Clinical follow-up will continue through three years, and enrollment for the European arm of a trial evaluating a drug-eluting version of the Formula stent for renal indications is scheduled to be announced at the LINC meeting in Germany later this month.

 

Never miss a healthcare headline

Healthcare moves fast โ€“ stay on top of it with our must - read briefings.

  • The top hospital and healthcare stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments transforming global healthcare management

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media PackNow

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Latest stories

Related stories

The Cigna Group Partners with OpenAI to Enhance Oncology Care Workflows

The Cigna Group has entered into a strategic partnership...

WHO Expands Prequalification Programme for Medical Devices

The World Health Organization (WHO) has announced a major...

GE HealthCare and Mass General Brigham Explore Generative AI in Radiotherapy

GE HealthCare and Mass General Brigham have initiated a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป